Eli Lilly's (NYSE:LLY) Retevmo (selpercatinib) has been granted traditional U.S. FDA approval for thyroid cancer in adults and pediatric cases.
https://seekingalpha.com/news/4115326-lilly-retevmo-gains-traditional-approval-in-thyroid-cancer
Eli Lilly's (NYSE:LLY) Retevmo (selpercatinib) has been granted traditional U.S. FDA approval for thyroid cancer in adults and pediatric cases.
https://seekingalpha.com/news/4115326-lilly-retevmo-gains-traditional-approval-in-thyroid-cancer
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.